Document is current
Any future updates will be listed below
-
Authors
Zigler, C. K. https://orcid.org/0000-0002-8996-7757
Li, Z.
Hernandez, A.
Randell, R. L. https://orcid.org/0000-0002-8009-8209
Mann, C. M.
Weitzman, E.
Schanberg, L. E. https://orcid.org/0000-0002-1913-6472
von Scheven, E.
Reeve, B. B.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (U19AR069522)
- License Information
-
More Information
Article History
Accepted: 29 September 2024
First Online: 14 October 2024
Declarations
:
: Dr. Zigler has received consultant honoraria from Emmes Corporation and travel support from the Rett Syndrome Research Trust. Dr. Randell receives support from the NIH and Lupus Foundation of America, and her spouse has financial relationships with Merck & Co and Biogen. Dr. Schanberg has research funding from BMS and PCORI. She serves on the DSMBs for Sanofi (Sarilumab) and UCB (certolizumab). Dr. von Scheven receives financial support from the Childhood Arthritis and Rheumatology Research Alliance for her role on Executive Committee. Dr. Reeve, in the past five years, has received consultant honoraria from Novartis Pharmaceuticals, the University of Florida, Northwestern University, Johns Hopkins University, and Regeneron Pharmaceuticals. Authors Dr. Weitzman, C.M. Mann, Z. Li, and A. Hernandez declare they have no financial interests.
